Navigation Links
Genesis Biopharma Director William H. Andrews, Ph.D., Profiled in Popular Science Feature Story
Date:7/15/2011

LOS ANGELES, July 15, 2011 /PRNewswire/ -- The current issue of Popular Science magazine includes a feature story profiling William H. Andrews, a member of the Genesis Biopharma, Inc. (OTC/BB: GNBP) Board of Directors, and his work on the anti-aging properties of the human telomerase gene.

The entire 11-page story, titled "The Man Who Would Stop Time" by Joseph Hooper, can be found at www.popsci.com

About Genesis Biopharma, Inc.

Genesis Biopharma, Inc. is a development-stage biotechnology company engaged in the development of targeted cancer therapies. For more information about the company, visit www.genesis-biopharma.com.


'/>"/>
SOURCE Genesis Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Laszlo Radvanyi, Ph.D. Joins Genesis Biopharma Scientific and Medical Advisory Board
2. Genesis Biopharma Conference Call and Webcast Reminder
3. Genesis Biosciences Receives Pulire Innovation Award for e card Sanitary Bin Treatment Product
4. Patrick Hwu, M.D., and Mario Sznol, M.D., Join Genesis Biopharmas Scientific and Medical Advisory Board
5. Governor Gray Davis Joins Genesis Biopharma as Chairman of Corporate Advisory Board
6. ThermoGenesis Announces China Customer Implements Cord Blood Products
7. Tissue Genesis Begins FDA-Approved Clinical Trial
8. CryoLife Amends Tender Offer Related to its Proposed Acquisition of Cardiogenesis Corporation
9. Organogenesis, Life Sciences Center Break Ground on Worlds Largest Automated Living Cell Manufacturing Plant
10. Announcing ValGenesis On-Demand SaaS Solution
11. Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... AxioMed president, Jake Lubinski, describes ... characteristics when deformed, which is identical to how the human discs work to ... and return to its natural state along a hysteresis curve, exactly like a ...
(Date:3/23/2017)... -- GlobeImmune, Inc. today announced it has entered into a ... of its common stock to NantCell, Inc., a member ... sale of its common stock, NantCell has agreed to ... 200,000 shares, an estimated $2.0 million in value, of ... to enter into this strategic agreement with NantCell," said ...
(Date:3/23/2017)... York , March 23, 2017 According ... plasma products and derivatives market is fragmented due to the presence of ... such as Proliant, Thermo Fisher , and Sigma-Aldrich, compete with ... these three companies, collectively, held more than 76% of this market ... As ...
(Date:3/22/2017)... ... March 22, 2017 , ... Researchers face a ... lab samples to full-size tissues, bones, even whole organs to implant in people ... delivers blood deep into the developing tissue. , Current bioengineering techniques, including ...
Breaking Biology Technology:
(Date:2/10/2017)... Feb 10, 2017 Research and ... "Personalized Medicine - Scientific and Commercial Aspects" to ... ... Diagnosis is integrated with therapy for selection of treatment as ... detection and prevention of disease in modern medicine. Biochip/microarray technologies ...
(Date:2/8/2017)... YORK , Feb. 8, 2017 About ... individual,s voice to match it against a stored ... such as pitch, cadence, and tone are compared ... require minimal hardware installation, as most PCs already ... for different transactions. Voice recognition biometrics are most ...
(Date:2/8/2017)... Report Highlights ... The global synthetic-biology market reached nearly $3.9 billion in ... a compound annual growth rate (CAGR) of 24.0% through 2021. ... for synthetic biology. - Analyses of global market trends, with ... annual growth rates (CAGRs) through 2021. - Coverage of core ...
Breaking Biology News(10 mins):